Travere Therapeutics, Inc. (TVTX) Income Statement
TVTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTVTX revenue and net income
Where TVTX's revenue goes
2025Each bar shows an amount and its share of revenue. TVTX kept −5.2% of revenue as net income.
TVTX profit margins
TVTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +110.5% | +64.9% | +19.9% | +17.3% |
| Gross profit | +113.1% | +66.0% | +20.1% | +17.3% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | +13.7% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TVTX quarterly EPS vs estimates
Travere Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: October 29, 2026 (estimate $0.05).
TVTX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M | $198.3M | $175.3M | $164.2M | $154.9M | $133.6M |
| Cost of revenue | $10.3M | $7.7M | $11.4M | $4.4M | $3.8M | $6.1M | $5.2M | $5.5M | $3.6M | $4.6M |
| Gross profit | $480.4M | $225.4M | $133.8M | $105.0M | $128.0M | $192.2M | $170.1M | $158.7M | $151.3M | $129.0M |
| Research & development | $206.0M | $282.7M | $245.0M | $227.3M | $201.2M | $131.8M | $141.0M | $123.8M | $78.2M | $70.9M |
| Sales, general & admin | $337.2M | $264.1M | $265.5M | $197.5M | $126.3M | $135.8M | $129.0M | $103.7M | $104.0M | $98.0M |
| Total operating expenses | $543.2M | $549.3M | $521.9M | $424.9M | $327.4M | $368.4M | $269.9M | $227.4M | $182.1M | $168.9M |
| Operating income | −$62.8M | −$323.8M | −$388.1M | −$319.8M | −$199.4M | −$176.2M | −$99.8M | −$80.0M | −$53.8M | −$58.2M |
| Interest income | $12.7M | $17.8M | $21.8M | $6.3M | $2.0M | $5.0M | $10.1M | $5.5M | — | — |
| Interest expense | $10.7M | $11.2M | $11.3M | $11.0M | $19.7M | $19.1M | $18.8M | $9.8M | $4.4M | $4.7M |
| Income before taxes | −$49.3M | −$320.5M | −$376.1M | −$331.2M | −$216.9M | −$188.8M | −$146.4M | −$101.9M | −$58.4M | −$57.6M |
| Income taxes | $988,000 | $120,000 | $223,000 | $313,000 | $409,000 | −$19.4M | −$21,000 | $811,000 | $1.4M | −$9.7M |
| Net income | −$25.5M | −$321.5M | −$111.4M | −$278.5M | −$180.1M | −$169.4M | −$146.4M | −$102.7M | −$59.7M | −$47.9M |
| EBITDA | $22.2M | −$265.8M | −$326.2M | −$299.4M | −$184.5M | −$145.2M | −$107.2M | −$73.4M | −$38.7M | −$38.8M |
| EPS (diluted) | $0.90 | −$3.09 | −$0.26 | −$3.26 | −$1.68 | −$1.01 | −$2.13 | −$1.25 | −$0.26 | −$0.11 |
| Gross margin | 97.9% | 96.7% | 92.1% | 96.0% | 97.1% | 96.9% | 97.0% | 96.6% | 97.7% | 96.6% |
| Operating margin | −12.8% | −138.9% | −267.2% | −292.2% | −151.3% | −88.8% | −56.9% | −48.7% | −34.7% | −43.6% |
| Net margin | −5.2% | −137.9% | −76.7% | −254.4% | −136.6% | −85.4% | −83.5% | −62.5% | −38.6% | −35.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $169.6M | $127.2M | $129.7M | $164.9M | $114.4M | $81.7M | $74.8M | $62.9M | $54.1M | $41.4M | $45.1M | $37.1M |
| Cost of revenue | $2.2M | $26.8M | $2.6M | $1.6M | $1.5M | $4.7M | $2.6M | $1.6M | $12.4M | $1.5M | $16.4M | $1.3M |
| Gross profit | $167.4M | $100.4M | $127.1M | $163.3M | $112.9M | $77.1M | $72.2M | $61.3M | $41.7M | $39.9M | $28.6M | $35.8M |
| Research & development | $60.3M | $57.1M | $57.9M | $51.9M | $49.4M | $46.9M | $62.1M | $51.7M | $54.3M | $114.6M | $58.7M | $60.6M |
| Sales, general & admin | $96.1M | $80.3M | $101.7M | $86.5M | $76.2M | $72.8M | $69.5M | $65.6M | $64.8M | $64.2M | $63.6M | $67.8M |
| Total operating expenses | $163.5M | $137.3M | $159.6M | $138.3M | $125.6M | $119.7M | $133.0M | $117.4M | $108.8M | $179.1M | $111.5M | $128.4M |
| Operating income | $4.0M | −$36.9M | −$32.4M | $24.9M | −$12.7M | −$42.7M | −$60.7M | −$56.1M | −$67.1M | −$139.2M | −$82.8M | −$92.6M |
| Interest income | $3.4M | $2.6M | $2.6M | $3.0M | $3.3M | $3.8M | $3.8M | $3.6M | $4.4M | $6.0M | $7.2M | $5.8M |
| Interest expense | $2.1M | $2.3M | $2.3M | $2.8M | $2.8M | $2.9M | $2.8M | $2.8M | $2.8M | $2.8M | $2.8M | $2.8M |
| Income before taxes | −$35.0M | −$36.7M | −$21.1M | $25.7M | −$12.7M | −$41.2M | −$60.3M | −$54.8M | −$69.6M | −$135.8M | −$88.5M | −$89.2M |
| Income taxes | −$204,000 | −$120,000 | $921,000 | $8,000 | $20,000 | $39,000 | −$72,000 | −$84,000 | $85,000 | $191,000 | $68,000 | $12,000 |
| Net income | −$34.8M | −$37.1M | $2.7M | $25.7M | −$12.8M | −$41.2M | −$60.3M | −$54.8M | −$70.4M | −$136.1M | −$90.2M | $150.7M |
| EBITDA | −$28.6M | −$9.2M | −$632,000 | $44.3M | $4.1M | −$25.5M | −$45.4M | −$40.8M | −$56.4M | −$123.1M | −$73.9M | −$74.9M |
| EPS (diluted) | −$0.37 | $0.05 | $0.37 | $0.59 | $0.13 | −$0.19 | −$0.47 | −$0.46 | −$0.65 | −$1.51 | −$0.94 | $2.27 |
| Gross margin | 98.7% | 79.0% | 98.0% | 99.0% | 98.7% | 94.3% | 96.6% | 97.4% | 77.1% | 96.4% | 63.6% | 96.5% |
| Operating margin | 2.3% | −29.0% | −25.0% | 15.1% | −11.1% | −52.2% | −81.2% | −89.3% | −123.9% | −336.5% | −183.8% | −249.6% |
| Net margin | −20.5% | −29.2% | 2.1% | 15.6% | −11.1% | −50.4% | −80.6% | −87.1% | −130.1% | −328.9% | −200.1% | 406.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TVTX's financial statements (latest annual report filed February 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TVTX financial results
In fiscal year 2025 (ended December 31, 2025), Travere Therapeutics reported revenue of $490.7 million, up 110.5% from the year before. It had a net loss of $25.5 million, a net profit margin of −5.2%. Diluted earnings per share came to $0.90. Over five years revenue grew at an average rate of 19.9% a year.
See the TVTX stock overview for the latest quote and news, or the TVTX chart for price history and technical indicators.
TVTX income statement FAQ
What is Travere Therapeutics's annual revenue?
Travere Therapeutics reported total revenue of $490.7 million for fiscal year 2025, which ended on December 31, 2025. That was up 110.5% from $233.2 million the previous year.
Is Travere Therapeutics profitable?
No. Travere Therapeutics reported a net loss of $25.5 million in fiscal 2025, a net profit margin of −5.2%; its operating margin was −12.8%.
What is Travere Therapeutics's gross margin?
Travere Therapeutics's gross margin was 97.9% in fiscal 2025: for every $100 of revenue, Travere Therapeutics kept $98 after the direct cost of its products and services.
How much does Travere Therapeutics spend on research and development?
Travere Therapeutics spent $206.0 million on research and development in fiscal 2025, 42.0% of revenue.
How fast is Travere Therapeutics growing?
Revenue grew 19.9% a year on average over the last five fiscal years, from $198.3 million to $490.7 million.
What are Travere Therapeutics's earnings per share?
Travere Therapeutics earned $0.90 per diluted share in fiscal 2025, compared with $-3.09 a year earlier.
When will Travere Therapeutics report its next earnings?
Travere Therapeutics is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes.
When does Travere Therapeutics's fiscal year end?
Travere Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 19, 2026.